Neuronetics - STIM Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STIM shares.
View STIM analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1-year target prices for Neuronetics' shares. Their STIM share price forecasts range from $7.00 to $12.00. On average, they expect the company's share price to reach $9.67 in the next twelve months. This suggests a possible upside of 231.1% from the stock's current price.
View analysts price targets for STIM or view top-rated stocks among Wall Street analysts.

Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM stock has decreased by 57.5% and is now trading at $2.92.
View the best growth stocks for 2023 here.

Neuronetics saw a increase in short interest in March. As of March 15th, there was short interest totaling 256,700 shares, an increase of 23.6% from the February 28th total of 207,700 shares. Based on an average trading volume of 266,600 shares, the short-interest ratio is presently 1.0 days. Approximately 1.0% of the shares of the company are short sold.
View Neuronetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our STIM earnings forecast.

Neuronetics, Inc. (NASDAQ:STIM) issued its earnings results on Tuesday, March, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.13. The business had revenue of $18.20 million for the quarter, compared to analyst estimates of $16.58 million. Neuronetics had a negative trailing twelve-month return on equity of 56.07% and a negative net margin of 56.99%.

ETFs with the largest weight of Neuronetics (NASDAQ:STIM) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).

Neuronetics updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $15.00 million-$16.00 million, compared to the consensus revenue estimate of $16.71 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

(STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Neuronetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cannell Capital LLC (11.93%), Schroder Investment Management Group (3.22%), Silvercrest Asset Management Group LLC (2.90%), Divisadero Street Capital Management LP (2.33%), Morgan Stanley (1.61%) and First Eagle Investment Management LLC (1.35%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends.

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STIM stock can currently be purchased for approximately $2.92.

Neuronetics (NASDAQ:STIM) has a market capitalization of $79.48 million and generates $65.21 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

The company employs 175 workers across the globe.

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206.